The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.
Christos SachpekidisHoda AnwarJulia WinklerAnnette Kopp-SchneiderLionel LarribereUwe HaberkornJessica C HasselAntonia Dimitrakopoulou-StraussPublished in: European journal of nuclear medicine and molecular imaging (2018)
The application of the recently proposed PERCIMT to interim 18F-FDG PET/CT provides a more sensitive predictor of final clinical response to immunotherapy than the application of the EORTC criteria in patients with metastatic melanoma.
Keyphrases